

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-4. (cancelled)

5. (currently amended) A humanized antibody that is a humanized form of a mouse antibody ~~VTm1-1, the mouse antibody being~~ characterized by a light chain variable region of SEQ ID NO:4 ~~shown in Fig. 1B~~ and a heavy chain variable region of SEQ ID NO:2 ~~shown in Fig. 1A~~, wherein the humanized antibody specifically binds to verotoxin II (VT2).

6. (currently amended) [An] A humanized antibody that competes with a mouse antibody characterized by a light chain variable region of SEQ ID NO:4 and a heavy chain variable region of SEQ ID NO:2 ~~VTm1-1~~ for specific binding to VT2 ~~and/or VT2 variant~~.

7. (currently amended) A humanized antibody of claim 5 ~~any of claim 1~~ comprising complementarity determining regions from the mouse ~~VTm1-1~~ antibody and heavy and light chain variable region frameworks from the human GF4 antibody heavy and light chain frameworks, provided that at least one position selected from the group consisting of L49, H29, H30, H49 and H98, is occupied by the amino acid present in the equivalent position of the mouse ~~VTm1-1~~ antibody heavy or light chain variable region framework, which humanized antibody specifically binds to verotoxin II with an affinity constant between 10^7 M^{-1} and ten-fold the affinity of the mouse ~~VTm1-1~~ VTm1.1 antibody.

8. (currently amended) The humanized antibody of claim 7, provided that each position selected from the group consisting of L49, H29, H30, H49 and H98 is occupied by the amino acid present in the equivalent position of the mouse ~~VTm1-1~~ antibody heavy or light chain variable region framework.

9. (original) The humanized antibody of claim 8, provided that at least one position selected from the group L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 is occupied by an amino acid present in the equivalent position of a human antibody heavy or light chain consensus sequence.

10. (original) The humanized antibody of claim 9, provided that each position selected from the group L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 is occupied by an amino acid present in the equivalent position of a human antibody heavy or light chain consensus sequence.

11. (currently amended) The humanized antibody of claim 5 ~~any of claim 1~~ comprising a heavy chain variable region ~~shown in Fig. 2A~~ of SEQ ID NO:6 and a light chain variable region of SEQ ID NO:8 ~~shown in Fig. 2B~~ provided that one or more positions selected from the group consisting of L49, H29, H30, H49, H98, L3, L4, L19, L76, L79, L85, H1, H4, H5, H79, H89 and H93 may be substituted as shown in Tables 2 and 3.

12. (currently amended) The humanized antibody of claim 5 ~~any of claim 1~~, comprising a heavy chain variable region ~~shown in Fig. 2A~~ of SEQ ID NO:6 and a light chain variable region of SEQ ID NO:8 ~~shown in Fig. 2B~~.

13. (currently amended) The humanized antibody of claim 5 ~~any of claim 1~~, comprising a humanized heavy chain having at least 85% identity with the humanized heavy chain of SEQ ID NO:6 ~~shown in Fig. 2A~~ and a humanized light chain having at least 85% sequence identity with the humanized light chain of SEQ ID NO:8 ~~shown in Fig. 2B~~, provided that at least one position selected from the group consisting of L49, H29, H30, H49 and H98, is occupied by the amino acid present in the equivalent position of the mouse ~~VTml-1~~ VTml.1 antibody heavy or light chain variable region framework.

14. (currently amended) The humanized antibody of claim 5 or 6 ~~any of claims 1-6~~, wherein the antibody comprises two pairs of light/heavy chain dimers, wherein each chain comprises a variable region and a constant region.

15. (currently amended) The humanized antibody of claim 5 or 6 ~~any of claim 1~~, which is a Fab fragment or a F(ab')₂.

16. (currently amended) The humanized antibody of claim 5 or 6 ~~any of claim 1~~ in purified form.

17. (currently amended) The humanized antibody of claim 5 or 6 ~~any of claim 1~~, which has an IgG₁ immunoglobulin isotype.

18. (currently amended) A method of producing a humanized V_HTm1-1 antibody, comprising culturing a cell line, which encodes heavy and light chain chains of the humanized antibody of claim 5 or 6 ~~any of claim 1~~, whereby the humanized antibody is expressed; and recovering the humanized antibody expressed by the cell line.

19. (original) The method of claim 18, further comprising mixing the antibody with a pharmaceutically acceptable carrier to produce a pharmaceutical composition.

20. (currently amended) A pharmaceutical composition comprising the humanized antibody of claim 5 or 6 ~~any of claims 1-6~~ and a pharmaceutically acceptable carrier.

21. (original) A pharmaceutical composition comprising the humanized antibody of claim 12 and a pharmaceutically acceptable carrier.

22. (currently amended) A method of treating a patient suffering or at risk of toxic effects from a verotoxin, comprising administering to the patient an effective dosage of a

human or humanized antibody that specifically binds to verotoxin II, wherein the humanized antibody is as defined in claim 5 or claim 6 and/or verotoxin II variant.

23. (currently amended) The method of claim 22, wherein the antibody competes with a mouse antibody characterized by a light chain variable region of SEQ ID NO:4 and a heavy chain variable region of SEQ ID NO:2 ~~VTm1-1~~ for specific binding to VT2 ~~verotoxin II or verotoxin II variant.~~

24. (cancel)

25. (currently amended) The method of claim 22, wherein the humanized antibody specifically binds to the B subunit of VT2 ~~and/or VT2 variant.~~

26-28. (cancel)

29. (currently amended) The method of claim 22, wherein the antibody is a humanized antibody comprising a heavy chain variable region ~~shown in Fig. 2A of SEQ ID NO:6~~ and a light chain variable region ~~shown in Fig. 2A of SEQ ID NO:8.~~

30. (original) The method of claim 22, wherein the patient is infected with verotoxin producing *E. coli* and the antibody is administered therapeutically.

31. (original) The method of claim 22, wherein the patient is at risk of infection by verotoxin producing *E. coli* and the antibody is administered prophylactically.

32. (currently amended) The method of claim 30, further comprising monitoring the patient for recovery from the toxic effects of VT2 ~~verotoxin II or verotoxin II variant.~~

PATENT

Docket No.: 019026-000110US

Client Ref. No.: T-400

33. (currently amended) A cell line that produces the antibody of claim 5 or 6
~~any of claim 1.~~